Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
Authors
Robert R. McWilliams
Mayo Clinic, Rochester, MN
Robert R. McWilliams, Shernan Holtan, Gregory Russell Pond, Yousef Zakharia, Brendan D. Curti, Evidio Domingo Musibay, Anthony J. Olszanski, Lisa A. Kottschade, Ralph J. Hauke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT03241186
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr TPS65)
Abstract #
TPS65
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
First Author: Lisa A. Kottschade
Poster
2023 ASCO Annual Meeting
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in CheckMate 238.
First Author: Mahrukh M. Syeda
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin
First Author: Sylvie Lorenzen